Change of Nerve Conduction Properties in IVIg Dependent Neuropathies

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by University of Cologne
Sponsor:
Information provided by (Responsible Party):
Helmar Lehmann, University of Cologne
ClinicalTrials.gov Identifier:
NCT01655394
First received: July 30, 2012
Last updated: May 27, 2014
Last verified: May 2014
  Purpose

IVIg exert a variety of different immunomodulatory effects and several mechanism of action have been proposed for IVIg. In this study the role of IVIg on short term nerve conduction in patients with immune-mediated neuropathies will be explored.


Condition
Guillain-Barre Syndrome
CIDP
Multifocal Motor Neuropathy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Change of Nerve Conduction Properties in IVIg Dependent Neuropathies

Resource links provided by NLM:


Further study details as provided by University of Cologne:

Estimated Enrollment: 50
Study Start Date: October 2012
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

patients with immune neuropathies

Criteria

Inclusion Criteria:

  • immune neuropathy
  • age above 18 y
  • IVIg treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01655394

Contacts
Contact: Helmar C. Lehmann, PD Dr. med. helmar.lehmann@uk-koeln.de

Locations
Germany
University of Cologne Recruiting
Cologne, Germany
Contact: Helmar Lehmann, MD         
Sponsors and Collaborators
University of Cologne
Investigators
Principal Investigator: Helmar C. Lehmann, PD Dr. med. PI
  More Information

No publications provided

Responsible Party: Helmar Lehmann, PD Dr. med. H. Lehmann, University of Cologne
ClinicalTrials.gov Identifier: NCT01655394     History of Changes
Other Study ID Numbers: 01607831337
Study First Received: July 30, 2012
Last Updated: May 27, 2014
Health Authority: Germany: University of Cologne

Additional relevant MeSH terms:
Guillain-Barre Syndrome
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Neuromuscular Diseases
Peripheral Nervous System Diseases
Polyneuropathies
Polyradiculoneuropathy

ClinicalTrials.gov processed this record on October 20, 2014